Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brain cancer vaccine - Northwest Biotherapeutics

Drug Profile

Brain cancer vaccine - Northwest Biotherapeutics

Alternative Names: DCVax-Brain; DCVax-Brain personalised immune therapy - Northwest Biotherapeutics; DCVax-L; DCVax-L (Glioblastoma)

Latest Information Update: 25 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwest Biotherapeutics
  • Developer Northwest Biotherapeutics; University of Pennsylvania
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Glioblastoma
  • Phase I/II Ovarian cancer

Most Recent Events

  • 20 Dec 2023 Preregistration for Glioblastoma (Newly diagnosed) in United Kingdom (Intradermal)
  • 20 Dec 2023 Preregistration for Glioblastoma (Recurrent) in United Kingdom (Intradermal)
  • 12 Sep 2023 Northwest Biotherapeutics completes phase-I/II clinical trials in Ovarian cancer (Late-stage disease) in USA, prior to September 2023(Intradermal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top